Moderna, Inc. $MRNA Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 4.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 75,068 shares of the company’s stock after acquiring an additional 3,183 shares during the period. ProShare Advisors LLC’s holdings in Moderna were worth $2,071,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in MRNA. SHANDA ASSET MANAGEMENT HOLDINGS Ltd purchased a new stake in shares of Moderna in the first quarter valued at about $28,350,000. Jacobs Levy Equity Management Inc. purchased a new stake in Moderna in the 1st quarter valued at approximately $28,308,000. Jump Financial LLC lifted its stake in Moderna by 5,590.0% in the 1st quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock valued at $25,584,000 after buying an additional 886,567 shares in the last quarter. Invesco Ltd. grew its holdings in Moderna by 17.5% during the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock valued at $166,801,000 after buying an additional 877,162 shares during the last quarter. Finally, Sessa Capital IM L.P. purchased a new position in Moderna during the first quarter worth $21,066,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Trading Down 0.8%

Shares of Moderna stock opened at $24.77 on Friday. The business’s fifty day moving average price is $25.92 and its 200 day moving average price is $27.07. Moderna, Inc. has a twelve month low of $23.04 and a twelve month high of $48.92. The stock has a market capitalization of $9.68 billion, a P/E ratio of -3.07 and a beta of 2.02.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($2.15) by $1.64. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The company’s quarterly revenue was down 45.4% compared to the same quarter last year. During the same period last year, the business posted $0.03 EPS. Moderna has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. UBS Group reduced their price objective on Moderna from $70.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, October 23rd. Evercore ISI set a $32.00 target price on shares of Moderna in a research note on Friday, August 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moderna in a report on Wednesday, October 8th. Finally, Leerink Partners reduced their price objective on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research note on Friday, August 22nd. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have given a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, Moderna currently has an average rating of “Hold” and an average price target of $35.85.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.